Abstract
Pentadecylidenemalonate 1b, a simplified analogue of anacardic acid, was identified as the first mixed activator/inhibitor of histone acetyltransferases (HATs). It potentiates PCAF HAT activity while inhibiting those of p300/CBP and recombinant CBP. The remarkable apoptotic effect together with the ability to selectively acetylate histone versus non-histone substrates appoint 1b as a lead for the development of anticancer drugs.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetylation
-
Alkadienes / chemistry*
-
Antineoplastic Agents* / chemistry
-
Antineoplastic Agents* / pharmacology
-
Apoptosis / drug effects*
-
Apoptosis / physiology
-
Cell Cycle / drug effects*
-
Cell Cycle / physiology
-
Enzyme Inhibitors* / chemistry
-
Enzyme Inhibitors* / pharmacology
-
Histone Acetyltransferases / antagonists & inhibitors*
-
Humans
-
Malonates / chemistry*
-
Models, Chemical
-
U937 Cells
-
p300-CBP Transcription Factors / antagonists & inhibitors
Substances
-
Alkadienes
-
Antineoplastic Agents
-
Enzyme Inhibitors
-
Malonates
-
pentadecylidenemalonate 1b
-
Histone Acetyltransferases
-
p300-CBP Transcription Factors
-
p300-CBP-associated factor